External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? - PubMed (original) (raw)
Review
External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?
C Saunders et al. Diabet Med. 2013 Mar.
Abstract
Aims: To describe the proportion of people with Type 2 diabetes living in Scotland who meet eligibility criteria for inclusion in several large randomized controlled trials of glycaemic control to inform physicians and guideline developers about the generalizibility of trial results.
Methods: A literature review was performed to identify large trials assessing the impact of glycaemic control on risk of macrovascular disease. Inclusion and exclusion criteria from each trial were applied to data on the population of people with a diagnosis of Type 2 diabetes living in Scotland in 2008 (n = 180,590) in a population-based cross-sectional study and the number and proportion of people eligible for each trial was determined.
Results: Seven trials were identified. The proportion of people with Type 2 diabetes who met the eligibility criteria for the trials ranged from 3.5 to 50.7%. Trial participants were younger at age of diagnosis of diabetes and at time of trial recruitment than in the Scottish study population. The application of upper age criteria excluded the largest proportion of patients, with up to 39% of people with Type 2 diabetes ineligible for a trial with the most stringent criteria based on age alone.
Conclusions: We found that many of the large trials of glycaemic control among people with Type 2 diabetes have limited external validity when applied to a population-based cohort of people with Type 2 diabetes. In particular, the age distribution of trial participants often does not reflect that of people with Type 2 diabetes in a contemporary British population.
© 2012 The Authors. Diabetic Medicine © 2012 Diabetes UK.
Comment in
- The external validity of randomized controlled trials; implications for clinical care.
Hitman GA. Hitman GA. Diabet Med. 2013 Mar;30(3):259. doi: 10.1111/dme.12139. Diabet Med. 2013. PMID: 23424998 No abstract available.
Similar articles
- Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.
Filion M, Forget G, Brochu O, Provencher L, Desbiens C, Doyle C, Poirier B, DuRocher M, Camden S, Lemieux J. Filion M, et al. Clin Trials. 2012 Oct;9(5):652-9. doi: 10.1177/1740774512456453. Clin Trials. 2012. PMID: 23060323 - Impact of deprivation on cardiovascular risk factors in people with diabetes: an observational study.
Wild S, Macleod F, McKnight J, Watt G, Mackenzie C, Ford I, McConnachie A, Lindsay RS. Wild S, et al. Diabet Med. 2008 Feb;25(2):194-9. doi: 10.1111/j.1464-5491.2008.02382.x. Diabet Med. 2008. PMID: 18290861 - Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance.
Lebovitz HE. Lebovitz HE. J Indian Med Assoc. 2008 Nov;106(11):724-6. J Indian Med Assoc. 2008. PMID: 19368098 - [Prevalence of newly diagnosed type 2 diabetes, impaired glucose tolerance and abnormal fasting glucose in a high risk population. Data from the RIAD study using new diagnostic criteria for diabetes].
Köhler C, Temelkova-Kurktschiev T, Schaper F, Fücker K, Hanefeld M. Köhler C, et al. Dtsch Med Wochenschr. 1999 Sep 17;124(37):1057-61. doi: 10.1055/s-2007-1024481. Dtsch Med Wochenschr. 1999. PMID: 10520305 German. - Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control.
Akalin S, Berntorp K, Ceriello A, Das AK, Kilpatrick ES, Koblik T, Munichoodappa CS, Pan CY, Rosenthall W, Shestakova M, Wolnik B, Woo V, Yang WY, Yilmaz MT; Global Task Force on Glycaemic Control. Akalin S, et al. Int J Clin Pract. 2009 Oct;63(10):1421-5. doi: 10.1111/j.1742-1241.2009.02165.x. Int J Clin Pract. 2009. PMID: 19769698
Cited by
- Patient-reported outcomes and healthcare resource utilization in systemic lupus erythematosus: impact of disease activity.
Touma Z, Costenbader KH, Hoskin B, Atkinson C, Bell D, Pike J, Berry P, Karyekar CS. Touma Z, et al. BMC Rheumatol. 2024 Jun 5;8(1):22. doi: 10.1186/s41927-023-00355-6. BMC Rheumatol. 2024. PMID: 38840229 Free PMC article. - Use of Real-World Data in Population Science to Improve the Prevention and Care of Diabetes-Related Outcomes.
Gregg EW, Patorno E, Karter AJ, Mehta R, Huang ES, White M, Patel CJ, McElvaine AT, Cefalu WT, Selby J, Riddle MC, Khunti K. Gregg EW, et al. Diabetes Care. 2023 Jul 1;46(7):1316-1326. doi: 10.2337/dc22-1438. Diabetes Care. 2023. PMID: 37339346 Free PMC article. Review. - Work-Related Productivity Loss and Associated Indirect Costs in Patients With Crohn's Disease or Ulcerative Colitis in the United States.
Ding Z, Muser E, Izanec J, Lukanova R, Kershaw J, Roughley A. Ding Z, et al. Crohns Colitis 360. 2022 Jun 15;4(3):otac023. doi: 10.1093/crocol/otac023. eCollection 2022 Jul. Crohns Colitis 360. 2022. PMID: 36777416 Free PMC article. - Timing of dialysis in acute kidney injury using routinely collected data and dynamic treatment regimes.
Morzywołek P, Steen J, Vansteelandt S, Decruyenaere J, Sterckx S, Van Biesen W. Morzywołek P, et al. Crit Care. 2022 Nov 28;26(1):365. doi: 10.1186/s13054-022-04252-1. Crit Care. 2022. PMID: 36443861 Free PMC article. - Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol.
Butterly E, Wei L, Adler AI, Almazam SAM, Alsallumi K, Blackbourn LAK, Dias S, Hanlon P, Hughes K, Lewsey J, Lindsay R, McGurnaghan S, Petrie J, Phillippo D, Sattar N, Tomlinson LA, Welton N, Wild S, McAllister D. Butterly E, et al. BMJ Open. 2022 Oct 27;12(10):e066491. doi: 10.1136/bmjopen-2022-066491. BMJ Open. 2022. PMID: 36302574 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous